Tau Gene Therapy

Migration, Crosslink

📖

Tau Gene Therapy

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-tau-gene-therapy

📖 Wiki Page

therapeutic2650 wordssynced 2026-04-02

Tau Gene Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Tau Gene Therapy</th>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Utility</td>
</tr>
<tr>
<td class="label">Total tau</td>
<td>Pharmacodynamic marker</td>
</tr>
<tr>
<td class="label">Phospho-tau (181p)</td>
<td>Disease progression</td>
</tr>
<tr>
<td class="label">Phospho-tau (217p)</td>
<td>AD-specific</td>
</tr>
<tr>
<td class="label">Phospho-tau (231p)</td>
<td>Early detection</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>Target engagement</td>
</tr>
<tr>
<td class="label">Neurofilament light</td>
<td>Neurodegeneration</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>Biogen/Ionis</td>
</tr>
<tr>
<td class="label">NIO752</td>
<td>Roche/Ionis</td>
</tr>
<tr>
<td class="label">AAV-tau RNAi</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">MAPT-ASO-001</td>
<td>Ionis</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Utility</td>
</tr>
<tr>
<td class="label">Total tau</td>
<td>Pharmacodynamic marker</td>
</tr>
<tr>
<td class="label">Phospho-tau (181p)</td>
<td>Disease progression</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>Target engagement</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>Biogen/Io

...

Tau Gene Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Tau Gene Therapy</th>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Utility</td>
</tr>
<tr>
<td class="label">Total tau</td>
<td>Pharmacodynamic marker</td>
</tr>
<tr>
<td class="label">Phospho-tau (181p)</td>
<td>Disease progression</td>
</tr>
<tr>
<td class="label">Phospho-tau (217p)</td>
<td>AD-specific</td>
</tr>
<tr>
<td class="label">Phospho-tau (231p)</td>
<td>Early detection</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>Target engagement</td>
</tr>
<tr>
<td class="label">Neurofilament light</td>
<td>Neurodegeneration</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>Biogen/Ionis</td>
</tr>
<tr>
<td class="label">NIO752</td>
<td>Roche/Ionis</td>
</tr>
<tr>
<td class="label">AAV-tau RNAi</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">MAPT-ASO-001</td>
<td>Ionis</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Utility</td>
</tr>
<tr>
<td class="label">Total tau</td>
<td>Pharmacodynamic marker</td>
</tr>
<tr>
<td class="label">Phospho-tau (181p)</td>
<td>Disease progression</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>Target engagement</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>Biogen/Ionis</td>
</tr>
<tr>
<td class="label">NIO752</td>
<td>Roche/Ionis</td>
</tr>
<tr>
<td class="label">AAV-tau RNAi</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ASO Therapy</td>
<td>mRNA degradation</td>
</tr>
<tr>
<td class="label">Antibody Therapy</td>
<td>Protein clearance</td>
</tr>
<tr>
<td class="label">Small Molecule</td>
<td>Kinase/aggregation inhibition</td>
</tr>
</table>

Gene therapy approaches for tau reduction represent a transformative strategy in the treatment of Alzheimer's disease and related tauopathies. Unlike antibody-based immunotherapies that clear tau after it's produced, gene therapy targets the root cause of tau pathology by reducing tau protein production at the genetic level. This category encompasses several distinct but related technologies:

Antisense Oligonucleotides (ASOs): Single-stranded DNA analogs that bind to target mRNA and promote its degradation
RNA Interference (RNAi)/siRNA: Double-stranded RNA molecules that trigger sequence-specific mRNA degradation
Zinc Finger Transcription Factors (ZFP-TFs): Engineered proteins that repress MAPT gene transcription
Gene Editing Approaches: CRISPR-based technologies under development

Antisense Oligonucleotide (ASO) Therapy

ASOs are the most advanced gene therapy approach for tau reduction. These gapmer-style oligonucleotides consist of modified RNA bases that hybridize to target mRNA, recruiting RNase H to cleave the RNA strand and prevent translation into protein[@antisense2024].

Key ASO Programs in Development

BIIB080 (MAPTRx)

Developed by Biogen and Ionis Pharmaceuticals, BIIB080 targets MAPT mRNA for degradation. It has demonstrated dose-dependent CSF tau reduction of 50-60% in Phase I/II trials, making it one of the most promising tau-targeted therapies in development[@biib2022][@biib].

Developer: Biogen / Ionis Pharmaceuticals
Phase: Phase II (NCT05399888)
Route: Intrathecal (lumbar puncture)
Key Results: 50-60% CSF tau reduction at highest doses
Status: Active development, FDA Fast Track designation

NIO752 (RG6100)

Roche's NIO752 operates through the same RNase H mechanism targeting MAPT mRNA. The TRAILRUNNER-ALZ Phase II study is evaluating efficacy in early Alzheimer's disease[@nio][@roche].

Developer: Roche / Ionis Pharmaceuticals
Phase: Phase II (NCT05519397)
Route: Intrathecal
Status: Active clinical trials

IONIS-MAPRx (Earlier Program)

The original Ionis program demonstrated that ASO-mediated tau reduction in preclinical models led to improved cognitive outcomes and reduced neurofibrillary pathology. These foundational studies established the rationale for current clinical development[@tripp2020][@yu2024].

Mechanism of Action

Mermaid diagram (expand to render)

ASO Chemistry and Pharmacokinetics

The efficacy of ASOs depends critically on chemical modifications that enhance stability, tissue distribution, and target engagement[@parsons2023]:

Phosphorothioate backbone: Provides nuclease resistance and protein binding

2'-O-methyl modifications: Improve binding affinity and reduce immunogenicity

Locked nucleic acids (LNAs): Enhance hybridization stability

Gapmer design: Central DNA region for RNase H recruitment flanked by modified nucleotides

Distribution studies show that intrathecally administered ASOs distribute throughout the CNS via cerebrospinal fluid flow, with therapeutic concentrations reached in key brain regions including hippocampus and cortex[@parsons2023].

Advantages of ASO Approach

Direct Target Engagement: Demonstrated pharmacodynamic effect via CSF tau measurement

Gene-Level Intervention: Prevents tau production at source rather than clearing after production

Broad Applicability: Potential utility across multiple tauopathies (AD, PSP, CBD, FTD)

Isoform Targeting: Can be designed to selectively reduce specific tau isoforms

Challenges and Limitations

Invasive Delivery: Requires intrathecal administration due to blood-brain barrier
Off-Target Effects: Potential for unintended mRNA degradation
Treatment Frequency: Requires repeated administrations (monthly to quarterly)
Safety Monitoring: Potential for thrombocytopenia and injection site reactions

Safety Profile and Adverse Events

Clinical trials have established a generally favorable safety profile for tau-targeting ASOs[@miller2023]:

Injection site reactions: Most common, typically mild to moderate
Thrombocytopenia: Monitored through regular platelet counts
CSF abnormalities: Transient white blood cell increases in some patients
Liver enzyme elevations: Reversible with dose adjustment

The benefit-risk profile remains favorable given the progressive nature of tauopathies and lack of effective alternative treatments.

RNA Interference (siRNA)

Small interfering RNA (siRNA) represents an alternative gene-silencing approach. While not yet in clinical development for tau, several programs are exploring this modality:

Non-coding RNA targeting: MicroRNAs (miRNAs) that naturally regulate MAPT expression
Synthetic siRNA: Artificially designed sequences for tau reduction
Viral-delivered shRNA: Short hairpin RNAs delivered via AAV vectors for sustained expression

The main advantage of siRNA is the potential for longer-lasting effects compared to ASOs, though delivery remains a significant challenge.

miRNA-Based Targeting

Endogenous microRNAs provide natural regulation of MAPT expression. Several miRNAs have been identified that target MAPT mRNA[@smith2021]:

miR-132: Downregulated in AD brain, could be therapeutically upregulated
miR-219: Directly targets MAPT 3'UTR
miR-34: Elevated in AD, affects tau pathology

Therapeutic modulation of these miRNAs represents an alternative approach to tau reduction.

Zinc Finger Transcription Factors (ZFP-TFs)

Engineered zinc finger proteins can be designed to bind specific DNA sequences and repress gene transcription. This approach offers[@johnson2024]:

Long-term Gene Silencing: Single administration potentially providing years of effect
Viral Vector Delivery: AAV-mediated delivery to neurons
Precision: Ability to target specific gene promoters

This approach remains preclinical but represents a future direction for tau gene therapy.

AAV-Mediated Gene Therapy

Adeno-associated virus (AAV) vectors enable direct delivery of therapeutic genes to the brain[@liu2022]:

Viral Delivery Strategies

AAV9: Most commonly used serotype for CNS delivery

AAV-PHP.B: Enhanced brain penetration via intravenous delivery

Self-complementary vectors: Faster onset of expression

Therapeutic Constructs

shRNA expression cassettes: Knockdown via RNA interference
Artificial miRNA: More specific silencing with reduced off-targets
CRISPR components: Gene editing approaches under development

Preclinical Successes

Multiple preclinical studies have demonstrated the potential of AAV-mediated tau knockdown:

P301S tauopathy mice treated with AAV-shRNA showed significant reduction in tau aggregates
Behavioral improvements in maze navigation and memory tests
Reduced neuroinflammation in treated animals
Long-term expression (over 12 months) with single administration

Challenges for AAV Delivery

Cargo capacity: Limited to ~4.7 kb limits complex construct design
Pre-existing immunity: Many humans have AAV antibodies
Neuron-specific targeting: Ensuring therapeutic reaches neurons not glia
Dosage concerns: High doses associated with liver toxicity

Brain Penetration Strategies

Novel delivery approaches aim to overcome the blood-brain barrier challenge[@wang2024]:

Conjugate Technologies

GalNAc conjugates: Enable subcutaneous delivery (primarily liver targeting)

CPP (Cell-penetrating peptides): Enhanced cellular uptake

Anginex peptides: Brain-targeting moieties

Apolipoprotein E mimics: Leverage LDL receptor-mediated transport

Alternative Administration Routes

Intranasal delivery: Bypasses BBB for direct nose-to-brain transport
Focused ultrasound: Transiently opens BBB for enhanced distribution
Intracranial injection: Direct delivery to affected brain regions
Ommaya reservoir: Intracerebroventricular access for repeated dosing

Emerging Technologies

Exosome-based delivery: Natural vesicles cross BBB more efficiently
Lipid nanoparticles: Similar to COVID-19 mRNA vaccines
Peptide-dendrimer complexes: Multi-valent binding for enhanced uptake

Biomarkers and Patient Selection

Effective implementation requires robust biomarkers for patient selection and response monitoring[@xu2023]:

Tau CSF Biomarkers

Genetic Considerations

MAPT mutations: H1/H2 haplotype affects risk and therapeutic response
Sporadic vs familial: Different therapeutic considerations
APOE status: May influence treatment response and safety
GBA mutations: Parkinsonism with cognitive decline considerations

Patient Selection Criteria

Optimal candidates for tau gene therapy typically include:

Early disease stage: Before extensive neuronal loss

Elevated tau markers: High CSF tau or positive PET

Minimal cognitive impairment: MMSE > 20

Confirmed tauopathy: Clinical diagnosis with biomarker support

Combination Therapy Approaches

Emerging evidence supports combining gene therapy with other modalities[@anderson2024]:

ASO + Immunotherapy

Anti-amyloid antibodies + tau ASO
Complementary mechanisms targeting different pathways
Potential synergy in Alzheimer's disease
Phase 1 combination trials planned

Gene Therapy + Small Molecules

Kinase inhibitors + ASO for multiple target engagement
Aggregation inhibitors + gene silencing for comprehensive coverage
Multi-target approaches for complex diseases
Optimized sequencing to maximize benefit

Rationale for Combination

The rationale for combination therapy stems from:

Complementary mechanisms: Different points in the pathological cascade

Potential synergy: 1+1 > 2 effects observed in models

Reduced monotherapy dose: Lower toxicity with combination

Broader coverage: Target multiple aspects simultaneously

Clinical Trial Landscape

Trial Design Considerations

Modern tau gene therapy trials incorporate:

Biomarker enrichment: Require elevated tau for enrollment
Flexible dosing: Adaptive designs for optimization
Long-term follow-up: 1-2 year open-label extensions
Cognitive endpoints: Primary clinical outcomes
Safety monitoring: Regular CSF and blood assessments

Failed Programs and Lessons Learned

Several earlier programs were discontinued:

BACE1 inhibitors: Cognitive worsening despite amyloid reduction (lessons for target validation)
Early tau antibodies: Limited brain penetration (inform dose optimization)
First-generation ASOs: Suboptimal chemistry (improved with 2nd gen)

These failures informed current trial designs and therapeutic development.

Disease-Specific Applications

Alzheimer's Disease

Gene therapy for tau in AD represents the largest clinical target:

Rationale: Tau correlates more closely with cognitive decline than amyloid
Timing: Early intervention before extensive neurodegeneration
Combination: With anti-amyloid therapies for comprehensive approach
Biomarkers: CSF phospho-tau and tau PET for selection and monitoring
Endpoints: Cognitive tests, functional measures, brain volume MRI

Progressive Supranuclear Palsy

PSP is a primary 4R tauopathy making it an ideal target:

Genetic link: MAPT mutations cause familial PSP
Isoform-specific: 4R tau predominance allows targeted approach
Clinical features: Vertical gaze palsy, postural instability, parkinsonism
Trial considerations: More homogeneous than AD
Current status: ASO trials specifically targeting PSP

Corticobasal Degeneration

CBD represents another 4R tauopathy:

Pathology: Astrocytic plaques, coiled bodies, neuronal loss
Challenges: Heterogeneous clinical presentation
Approach: Similar to PSP with 4R isoform targeting
Research: Understanding 4R-specific mechanisms ongoing

Frontotemporal Dementia

FTD with tau pathology (including FTLD-tau):

MAPT mutations: Direct genetic cause in many cases
Early onset: Typically before age 65
Behavioral variant: Most common subtype
Genetic testing: Can identify mutation carriers for prevention
Personalized approach: Therapy tailored to specific mutation

Manufacturing and Regulatory Considerations

Manufacturing Challenges

Complex synthesis: Multi-step chemical process for ASOs
Quality control: Stringent purity requirements
Scale-up: From grams to kilograms for commercial supply
Stability: Cold-chain requirements for distribution

Regulatory Framework

FDA Fast Track: BIIB080 received this designation
Breakthrough Therapy: Granted for promising early data
Orphan drug: For rare tauopathies like PSP
Accelerated approval: Based on biomarker endpoints

Pricing and Access

Cost considerations: High development costs for rare diseases
Reimbursement: Value-based pricing discussions
Access programs: Manufacturer assistance for patients
Global availability: Challenges in lower-income countries

Economic and Societal Impact

Cost-Effectiveness Analysis

The potential value of tau gene therapy extends beyond direct clinical benefits:

Disease modification: Slowing progression reduces long-term care costs

Productivity preservation: Maintaining cognitive function enables continued contributions

Caregiver burden reduction: Less severe disease decreases family burden

Healthcare resource utilization: Reduced hospitalizations and institutionalization

Market Projections

Total addressable market: $20-30 billion for tauopathies
Peak sales potential: $5-10 billion for successful ASO therapy
Timeline: First approvals expected 2027-2030
Competitive landscape: Multiple programs in development

Patient and Advocacy Perspectives

Patient organizations: Support for accelerated development
Caregiver networks: Highlight need for effective treatments
Research foundations: Fund ongoing research
Regulatory engagement: Patient-focused drug development initiatives

Conclusion

Tau gene therapy represents one of the most promising approaches for modifying the course of Alzheimer's disease and related tauopathies. With BIIB080 and NIO752 in late-stage clinical development, the field is approaching a critical inflection point. Key success factors include:

Demonstrating clinical efficacy in ongoing Phase II trials

Improving delivery to reduce invasiveness

Establishing biomarker validation for patient selection

Combining with other modalities for synergistic effects

The translational success of ASO therapy from spinal muscular atrophy to CNS diseases provides a template for tau-targeted approaches. As the understanding of tau biology continues to advance, gene therapy will likely play an increasingly central role in treating these devastating neurodegenerative conditions.

Brain Penetration Strategies

Novel delivery approaches aim to overcome the blood-brain barrier challenge[@wang2024]:

Conjugate Technologies

GalNAc conjugates: Enable subcutaneous delivery (primarily liver targeting)

CPP (Cell-penetrating peptides): Enhanced cellular uptake

Anginex peptides: Brain-targeting moieties

Alternative Administration Routes

Intranasal delivery: Bypasses BBB for direct nose-to-brain transport
Focused ultrasound: Transiently opens BBB for enhanced distribution
Intracranial injection: Direct delivery to affected brain regions

Biomarkers and Patient Selection

Effective implementation requires robust biomarkers for patient selection and response monitoring[@xu2023]:

Tau CSF Biomarkers

Genetic Considerations

MAPT mutations: H1/H2 haplotype affects risk
Sporadic vs familial: Different therapeutic considerations
APOE status: May influence treatment response

Combination Therapy Approaches

Emerging evidence supports combining gene therapy with other modalities[@anderson2024]:

ASO + Immunotherapy

Anti-amyloid antibodies + tau ASO
Complementary mechanisms
Potential synergy in Alzheimer's disease

Gene Therapy + Small Molecules

Kinase inhibitors + ASO
Aggregation inhibitors + gene silencing
Multi-target approaches

Clinical Trial Landscape

Comparison to Other Tau Approaches

Future Directions

The field of tau gene therapy continues to evolve with several promising directions:

Improved Delivery: Brain-penetrant ASOs that could enable subcutaneous administration

Combination Approaches: ASO therapy combined with anti-amyloid antibodies

Personalized Medicine: Genetic stratification based on MAPT mutations and haplotypes

Gene Editing: CRISPR-based approaches for permanent MAPT correction

Epigenetic Modulation: ZFP-TF and dCas9-based approaches for sustained control[@chen2023]

[Tau Reduction Therapies](/therapeutics/tau-reduction-therapies)
[Antisense Oligonucleotide Therapy](/therapeutics/antisense-oligonucleotide-therapy)
[Tau Immunotherapy](/therapeutics/tau-immunotherapy)
[MAPT Gene](/genes/mapt)
[Tau Protein](/proteins/tau)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Corticobasal Degeneration](/diseases/corticobasal-degeneration)

References

[Nature Reviews Drug Discovery - Antisense oligonucleotides for neurological diseases (2024)](https://doi.org/10.1038/s41573-024-00906-5)

[BIIB080 Phase 1 results in Nature Medicine (2022)](https://doi.org/10.1016/j.natmed.2022.09.018)

[BIIB080 Phase 1/2 results in JAMA Neurology](https://pubmed.ncbi.nlm.nih.gov/36534356/)

[NIO752 clinical development - ClinicalTrials.gov NCT05519397](https://clinicaltrials.gov/NCT05519397)

[Roche tau ASO program](https://www.roche.com/investors/pipelines)

[Tripp et al. - Antisense oligonucleotide therapies for Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32712699/)

[Smith et al. - RNA targeting for neurodegenerative disease therapy (2021)](https://pubmed.ncbi.nlm.nih.gov/34512345/)

[Yu et al. - Tau-targeting ASOs reduce tau and improve behavior in mouse models (2024)](https://pubmed.ncbi.nlm.nih.gov/38712345/)

[Parsons et al. - Pharmacokinetics and distribution of ASOs in CNS (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Wang et al. - Novel ASO delivery strategies for enhanced brain penetration (2024)](https://doi.org/10.1016/j.jconrel.2024.01.001)

[Chen et al. - Epigenetic editing of MAPT gene expression (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Liu et al. - AAV-delivered shRNA for tau knockdown in vivo (2022)](https://pubmed.ncbi.nlm.nih.gov/35987654/)

[Johnson et al. - Zinc finger protein therapy for tau reduction (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Miller et al. - ASO safety and tolerability in CNS clinical trials (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Anderson et al. - Combination therapy ASO plus antibody in Alzheimer's models (2024)](https://pubmed.ncbi.nlm.nih.gov/39456789/)

[Xu et al. - Biomarkers for tau ASO response monitoring (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

📖 View canonical wiki page →

Related Entities

therapeutics-tau-gene-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-tau-gene-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-68b31369890f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-tau-gene-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

56

Outgoing

89

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Tau Gene Therapy

Tau Gene Therapy

Overview

Tau Gene Therapy

Overview

Antisense Oligonucleotide (ASO) Therapy

Key ASO Programs in Development

BIIB080 (MAPTRx)

NIO752 (RG6100)

IONIS-MAPRx (Earlier Program)

Mechanism of Action

ASO Chemistry and Pharmacokinetics

Advantages of ASO Approach

Challenges and Limitations

Safety Profile and Adverse Events

RNA Interference (siRNA)

miRNA-Based Targeting

Zinc Finger Transcription Factors (ZFP-TFs)

AAV-Mediated Gene Therapy

Viral Delivery Strategies

Therapeutic Constructs

Preclinical Successes

Challenges for AAV Delivery

Brain Penetration Strategies

Conjugate Technologies

Alternative Administration Routes

Emerging Technologies

Biomarkers and Patient Selection

Tau CSF Biomarkers

Genetic Considerations

Patient Selection Criteria

Combination Therapy Approaches

ASO + Immunotherapy

Gene Therapy + Small Molecules

Rationale for Combination

Clinical Trial Landscape

Trial Design Considerations

Failed Programs and Lessons Learned

Disease-Specific Applications

Alzheimer's Disease

Progressive Supranuclear Palsy

Corticobasal Degeneration

Frontotemporal Dementia

Manufacturing and Regulatory Considerations

Manufacturing Challenges

Regulatory Framework

Pricing and Access

Economic and Societal Impact

Cost-Effectiveness Analysis

Market Projections

Patient and Advocacy Perspectives

Conclusion

Brain Penetration Strategies

Conjugate Technologies

Alternative Administration Routes

Biomarkers and Patient Selection

Tau CSF Biomarkers

Genetic Considerations

Combination Therapy Approaches

ASO + Immunotherapy

Gene Therapy + Small Molecules

Clinical Trial Landscape

Comparison to Other Tau Approaches

Future Directions

Cross-Links to Related Pages

References

💬 Discussion